SEC Filings
Guardant Health Raises $550 Million With No Regular Interest To Replace 2027 Debt
The cancer-testing company paid approximately $501.7 million to retire $395.2 million in debt principal and bought conversion protection.
Guardant Health (GH) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The cancer-testing company paid approximately $501.7 million to retire $395.2 million in debt principal and bought conversion protection.
Earnings
Shield screening revenue grew 180%, while higher spending accompanied an increase in the company's annual sales outlook.
Earnings
Guardant raised its full-year screening outlook after Shield sales hit $68 million, though a billing-code gap will delay some cash.
SEC Filings
FMR, run by Chair and CEO Abigail P. Johnson, reports 7.7 million Guardant shares as of September 30, held in the ordinary course of business.
SEC Filings
Sayer, Dexcom's former CEO, takes a Class II seat, and Guardant also named Robert Parks its chief accounting officer.
SEC Filings
The awards pay nothing below the 40th percentile of relative shareholder return and top out at 250% of target.